Dataset from A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone Versus Eplerenone
收藏NIAID Data Ecosystem2026-05-02 收录
下载链接：
https://doi.org/10.25934/PR00008550
下载链接
链接失效反馈官方服务：
资源简介：
To assess a new drug, BAY94-8862, given orally at different doses, to evaluate whether it was
safe and can help the well-being of patients with worsening chronic heart failure and either
type II diabetes with or without chronic kidney disease or kidney disease alone. These
treatment doses were compared to eplerenone, another marketed drug approved to treat heart
failure.
创建时间：
2024-11-26
